- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03314168
Adaptations to Breast Cancer and Exercise (ABRACE)
May 2, 2022 updated by: João Henkin
Effects of Different Volumes of Combined Training on Neuromuscular Parameters of Women in Initial Treatment for Breast Cancer: A Randomized Controlled Trial
This study aims to investigate the effects of different volumes of combined training on fatigue, neuromuscular variables, morphological, cardiorespiratory capacity, functionality, and quality of life, in breast cancer (BCa) women undergoing primary treatment.
Two thirds will be the intervention group that will perform combined training, while the other third will be the control group that will have physiotherapy sessions.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Although chemotherapy and radiation are mainstream treatment modalities, patients will often experience treatment-related side effects such as impairments to the neuromuscular and cardiovascular systems and reduction in quality of life (QoL).To date, numerous positive effects on neuromuscular and aerobic parameters in response to resistance and aerobic training have been reported when both training modalities were simultaneously performed (i.e.
combined training - COMB) in BCa patients.
However, there is a lack of data regarding the prescription of this modality in BCa patients, as the necessary dose of resistance training for significant improve in fatigue, neuromuscular, and quality of life.
In this sense, no previous studies investigate the effect of different volumes of resistance training in BCa patients, providing important informations about the prescription in this clinical population.
Study Type
Interventional
Enrollment (Anticipated)
84
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Joao Henkin, BsC
- Phone Number: +5551 99302 3340
- Email: joaohenkin@gmail.com
Study Locations
-
-
-
Pôrto Alegre, Brazil
- Recruiting
- Hospital Moinhos de Vento
-
Contact:
- Alessandra Morelle, Dr.
-
Pôrto Alegre, Brazil
- Recruiting
- Universidade Federal do Rio Grande do Sul
-
Contact:
- Ronei Pinto, phd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Breast cancer diagnostic at I and II stages;
- Adjuvant or neoadjuvant chemotherapy (≤50% of sessions completed);
- More than 18 years.
Exclusion Criteria:
- Current smoking
- Diabetic neuropathy;
- Hypertension uncontrolled;
- Heart failure;
- Clinical depression;
- Skeletal muscle impairment which not allow physical exercise.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Control group
Patients who are randomized in control group will receive the usual care in their respective hospital.
|
The usual care will be recommended to avoid systematic physical exercise for 3 months and will receive general clinical recommendations such as nutritional intake and lifestyle issues in their respective hospital.
|
|
Experimental: Single-set group
Patients who are randomized in Single-set (SS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle.
One-single set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between the exercises.
|
Resistance exercises performed with different volumes (i.e.
one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.
Other Names:
|
|
Experimental: Multiple-sets group
Patients who are randomized in Multiples-set (MS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle.
Regarding resistance exercises, three set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between sets and the exercises.
|
Resistance exercises performed with different volumes (i.e.
one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neuromuscular fatigue
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
Fatigue will be assessed by Fatigue index in isokinetic device.
|
Changes from baseline are assessed after the intervention (week 13)
|
|
Subjective fatigue
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
Fatigue will be assessed by Piper fatigue scale (PFS).
The PFS in its current form is composed of 22 numerically scaled, "0" to "10" items (i.e.
0, none fatigue; 10, severe fatigue) that measure four dimensions of subjective fatigue: behavioral/severity (6 items; # 2-7); affective meaning (5 items: # 8-12); sensory (5 items: # 13-17); and cognitive/mood (6 items: # 18-23).
These 22 items are used to calculate the four sub-scale/dimensional scores and the total fatigue scores.
|
Changes from baseline are assessed after the intervention (week 13)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body composition
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
Body composition will be assessed by Dual-energy X-ray absorptiometry
|
Changes from baseline are assessed after the intervention (week 13)
|
|
Muscle thickness
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
Muscle thickness will be assessed by ultrasound images of quadriceps femoris and biceps.
|
Changes from baseline are assessed after the intervention (week 13)
|
|
Echo intensity
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
Echo intensity is a grey scale for analyze the image that ranging from 0 (black) to 255 (white), and will be assessed by ultrasound images of quadriceps femoris and biceps.
|
Changes from baseline are assessed after the intervention (week 13)
|
|
VO2máx
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
VO2máx will be assessed by an incremental protocol in a cycle ergometer
|
Changes from baseline are assessed after the intervention (week 13)
|
|
Knee extension muscle strength
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
Knee extension muscle strength will be assessed by a bilateral 1-repetition maximum, reported in Kg.
|
Changes from baseline are assessed after the intervention (week 13)
|
|
Unilateral vertical bench press muscle strength
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
Unilateral vertical bench press muscle strength will be assessed by an unilateral 1-repetition maximum on both sides, reported in Kg.
|
Changes from baseline are assessed after the intervention (week 13)
|
|
Knee extension peak torque
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
Knee extension peak torque will be assessed by maximal voluntary isometric contraction on the right side, in a isokinetic dynamometer.
|
Changes from baseline are assessed after the intervention (week 13)
|
|
Quality of life assessed by European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30+Br23
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
Quality of life will be assessed by European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30+Br23.
The EORTIC is composed by 53 questions scaled "0" to "4", and "0" to "7".
These 53 items are used to compute four domains (i.e.
global, functions, symptoms, and BR23 functions).
|
Changes from baseline are assessed after the intervention (week 13)
|
|
Functional Performance: Timed-up and go test
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
The timed-up-and-go requires an individual to stand up from a seated position in a chair, walk 2.44m, turn around a cone, walk back to the chair and sit down.
|
Changes from baseline are assessed after the intervention (week 13)
|
|
Functional performance: 5-repetitions Sit-to-stand test
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
For the 5-repetition sit-to-stand test, participants are instructed to start the test in a seated position with arms folded across the chest.
After the start command, participants stand up until full knees extension and then back to a seated position.
The time is stopped when the participants touch the seat after five complete repetitions.
|
Changes from baseline are assessed after the intervention (week 13)
|
|
Functional performance: 30-seconds arm-curl
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
The arm-curl test determines the maximal number of times a 2kg dumbbell can be lifted with the dominant arm through elbow flexion in 30 seconds.
Participants start the test seated in a chair, with arms extended and forearm maintained in supinated position during full range of motion.
|
Changes from baseline are assessed after the intervention (week 13)
|
|
Functional Performance: Stair Climbing
Time Frame: Changes from baseline are assessed after the intervention (week 13)
|
For the stair-climbing test, participants are instructed to climb a 10-step staircase without skip steps or using the handrail (except in need of balance to prevent falls
|
Changes from baseline are assessed after the intervention (week 13)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ronei Pinto, PhD, Federal University of Rio Grande do Sul
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 7, 2017
Primary Completion (Anticipated)
December 31, 2024
Study Completion (Anticipated)
August 30, 2025
Study Registration Dates
First Submitted
October 10, 2017
First Submitted That Met QC Criteria
October 13, 2017
First Posted (Actual)
October 19, 2017
Study Record Updates
Last Update Posted (Actual)
May 6, 2022
Last Update Submitted That Met QC Criteria
May 2, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 72983017.3.0000.5347
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Control group
-
Tasly Pharmaceutical Group Co., LtdCompleted
-
Chengdu Sport UniversityNot yet recruiting
-
Hanlim Pharm. Co., Ltd.Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
The First Affiliated Hospital of Zhejiang Chinese...Not yet recruitingAdolescent Idiopathic ScoliosisChina
-
International University of La RiojaCompletedPsychosis | Therapy | PsychologicalSpain
-
The University of Hong Konghong Kong Cancer FundCompletedBreast Cancer | Yoga Therapy | Shoulder Joint Motion | Scar Contracture
-
Physicians Committee for Responsible MedicineMetropolitan Police Department of Washington, D.C.SuspendedDiabetes Mellitus, Type 2 | Overweight | Blood PressureUnited States
-
University of MaltaNot yet recruiting